Frank Witney - PerkinElmer Independent Director
| PKIDelisted Stock | USD 115.24 0.74 0.64% |
Director
Dr. Franklin R. Witney, Ph.D., is Independent Director of the Company. Dr. Witney most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corporationration, a market leading ion and high performance liquid chromatography company from 2009 to 2011. Prior to that, Dr. Witney served as Executive Vice President and Chief Commercial Officer of Affymetrix from 2008 to 2009, following its acquisition of Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer from 2002 to 2008. He previously held the role of President of PerkinElmers Drug Discovery Tools division following PerkinElmers acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at BioRad Laboratories beginning in 1983, leading that companys efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a postdoctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a MS degree in microbiology from Indiana University, as well as a BS degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporationrationration, as well as the Chairman of the Board of Gyros Protein Technologies AB, and a member of the board of RareCyte, Inc., Nexcelom Bioscience LLC, Emulate, Inc., and GenapSys, Inc., all of which are privately held, and is an Operating Partner at Ampersand Capital Partners. Dr. Witney brings to our board deep market knowledge and over 30 years of leadership experience across the life sciences, diagnostics and analytical instruments industries, including as a chief executive officer and board member. since 2016.
| Age | 67 |
| Tenure | 8 years |
| Phone | 781 663 6900 |
| Web | https://www.perkinelmer.com |
Frank Witney Latest Insider Activity
Tracking and analyzing the buying and selling activities of Frank Witney against PerkinElmer stock is an integral part of due diligence when investing in PerkinElmer. Frank Witney insider activity provides valuable insight into whether PerkinElmer is net buyers or sellers over its current business cycle. Note, PerkinElmer insiders must abide by specific rules, including filing SEC forms every time they buy or sell PerkinElmer'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Frank Witney over a year ago Acquisition by Frank Witney of 244 shares of PerkinElmer subject to Rule 16b-3 |
PerkinElmer Management Efficiency
The company has Return on Asset of 0.0369 % which means that on every $100 spent on assets, it made $0.0369 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0706 %, implying that it generated $0.0706 on every 100 dollars invested. PerkinElmer's management efficiency ratios could be used to measure how well PerkinElmer manages its routine affairs as well as how well it operates its assets and liabilities.PerkinElmer has 3.92 B in debt with debt to equity (D/E) ratio of 0.65, which is OK given its current industry classification. PerkinElmer has a current ratio of 1.98, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for PerkinElmer to invest in growth at high rates of return.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Berendt | Waters | 71 | |
| Edward Conard | Waters | 63 | |
| Raymond Stevens | Danaher | 57 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Francis deSouza | Illumina | 53 | |
| Stephen Chubb | Charles River Laboratories | 76 | |
| R Keith | Thermo Fisher Scientific | 52 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| Garheng Kong | Laboratory of | 45 | |
| Nancy Andrews | Charles River Laboratories | 63 | |
| Peter Neupert | Laboratory of | 65 | |
| Mala Anand | Agilent Technologies | 53 | |
| Martin Mackay | Charles River Laboratories | 65 | |
| Virginia Wilson | Charles River Laboratories | 66 | |
| Richelle Parham | Laboratory of | 53 | |
| Carol Burt | IQVIA Holdings | 62 | |
| Michael Kelly | Mettler Toledo International | 64 | |
| Dow Wilson | Agilent Technologies | 61 | |
| Tyler Jacks | Thermo Fisher Scientific | 59 | |
| James Fasano | IQVIA Holdings | 50 | |
Management Performance
| Return On Equity | 0.0706 | |||
| Return On Asset | 0.0369 |
PerkinElmer Leadership Team
Elected by the shareholders, the PerkinElmer's board of directors comprises two types of representatives: PerkinElmer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PerkinElmer. The board's role is to monitor PerkinElmer's management team and ensure that shareholders' interests are well served. PerkinElmer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PerkinElmer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Goldberg, Senior Vice President - Administration, General Counsel, Secretary | ||
| Samuel Chapin, Independent Director | ||
| Michel Vounatsos, Independent Director | ||
| James Mock, Chief Financial Officer, Senior Vice President | ||
| Sylvie Gregoire, Independent Director | ||
| Andrew Okun, Chief Accounting Officer, Vice President, Treasurer | ||
| Pascale Witz, Independent Director | ||
| Miriame Victor, Chief Commercial Officer, Senior Vice President | ||
| Peter Barrett, Independent Director | ||
| Deborah Butters, Chief Human Resource Officer, Senior Vice President | ||
| Frank Witney, Independent Director | ||
| Alexis Michas, Independent Non-Executive Chairman of the Board | ||
| Stephen Willoughby, VP ESG | ||
| Tajinder Vohra, Senior Vice President Global Operations | ||
| Prahlad Singh, Senior Vice President and President - Diagnostics | ||
| Robert Friel, Chairman, CEO and President and Member of Fin. Committee | ||
| Maxwell Krakowiak, VP CFO | ||
| Masoud Toloue, VP Diagnostics | ||
| Daniel Tereau, Senior Vice President Strategy and Business Development | ||
| Alexandros Michas, Independent Non-Executive Chairman of the Board |
PerkinElmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PerkinElmer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0706 | |||
| Return On Asset | 0.0369 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 22.3 B | |||
| Shares Outstanding | 126.41 M | |||
| Shares Owned By Insiders | 0.26 % | |||
| Shares Owned By Institutions | 86.25 % | |||
| Number Of Shares Shorted | 3.53 M | |||
| Price To Earning | 21.07 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in PerkinElmer Stock
If you are still planning to invest in PerkinElmer check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PerkinElmer's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |